Estimating the Global Burden of Snakebite Can Help To Improve Management

Jean-Philippe Chippaux

Lack of Antivenom: A Market Failure

Snakebite is a common medical emergency in developing countries in tropical regions. The only specific treatment is antivenom [1], but this is often unavailable in remote health centres, due to market failure [2,3].

In the 1980s in Africa, 150,000 to 200,000 doses of antivenom were sold annually, whereas current sales have fallen to less than 20,000 doses per year. The price of a vial of antivenom has risen by a multiple of 10 over the last 20 years. Today, with the global economic crisis, the treatment represents several months of the average income of rural families. In an emergency situation, there is insufficient time for families to sell their crops and livestock to buy the antivenom.

The main reasons that the antivenom manufacturers use to justify such a dramatic price increase are the complexity and cost of antivenom production. But there are three other reasons for the escalating costs. First, the antivenom market is unstable. Second, there is little financial incentive for pharmacists and health centres to sell antivenom because they reap only feeble profit margins. Finally, there are no comprehensive data on how many doses of antivenom are required and where they should be distributed.

Estimating the Global Burden

The first assessment of global snakebite incidence and mortality was undertaken by Swaroop and Grab in 1954 [4]. They estimated the number of snakebites (in fact envenomings at that time) and deaths respectively at 500,000 and 30,000–40,000 per year. The price of a vial of antivenom has risen by a multiple of 10 over the last 20 years. Today, with the global economic crisis, the treatment represents several months of the average income of rural families. In an emergency situation, there is insufficient time for families to sell their crops and livestock to buy the antivenom.

The main reasons that the antivenom manufacturers use to justify such a dramatic price increase are the complexity and cost of antivenom production. But there are three other reasons for the escalating costs. First, the antivenom market is unstable. Second, there is little financial incentive for pharmacists and health centres to sell antivenom because they reap only feeble profit margins. Finally, there are no comprehensive data on how many doses of antivenom are required and where they should be distributed.

In this issue of PLoS Medicine, H. Janaka de Silva and colleagues report on a new estimate of the worldwide morbidity and mortality of snakebite, using a more thorough and rigorous search for data [6]. The researchers obtained primary data in three ways: (1) searching for publications on snakebite, (2) extraction of country-specific mortality data from databases maintained by United Nations organizations, and (3) identification of grey literature by discussion with key informants. Their new study confirms that morbidity and mortality due to snakebite are very high. The annual number of snakebites could be as high as 5.5 million, and deaths could range from 20,000 to 94,000. These estimates have a wide interval because of the limitations of the sources used and uncertainties about the primary data.

Limitations in Epidemiological Research on Snakebite

Reporting of snakebite—and particularly envenoming—by health authorities is generally very poor in most developing countries. To evaluate snakebite incidence and mortality, researchers therefore rely upon systematic reviews of the medical literature. Most of the current, accessible primary studies use the basic method of retrospective compilation of hospital registers or statistics from medical services. Primary data may also be obtained from prospective surveys, which can give better information on symptoms, complications, or effectiveness of treatment, but such surveys take longer and are more expensive.

However, both types of health centre surveys—retrospective and prospective—only account for a proportion of all snakebites, since some patients fail to attend health centres. And in developing countries, most patients (60%–80%) who do arrive at health centres with snakebite do so after a considerable delay (sometimes several days after the bite) because they

The Perspective section is for experts to discuss the clinical practice or public health implications of a published article that is freely available online.
first attend a traditional healer. Delay in attending health centres has been well documented in Africa [3,7,8], and to a lesser extent in Asia [9,10] and Latin America [11,12].

One may assume that some snakebite victims die before reaching the health centre in due time (leading to underestimation of snakebite mortality), and others do not go to the health centre because they were cured (leading to underestimation of morbidity). Nevertheless, complications of snakebite leading to serious sequelae (amputations or neurologic deficits) are common. Certainly, snakebite morbidity is more likely to be underestimated than mortality because death is a less frequent outcome and probably better reported than envenoming.

An alternative study methodology uses household surveys to question a representative part of the population to estimate the incidence and mortality of snakebite in the community. This technique, recently validated by prospective follow-up of populations that confirmed its reliability [13], is a good complement to hospital surveys. However, although household snakebite surveys can be valuable and informative in helping to plan the community’s need for antivenom, this method is not yet well developed.

In the new study by de Silva and colleagues, the data were obtained from a limited number of studies, which were local and scattered. The main limitation of their study, as for similar types of evaluation, is the concern about how representative it is of the actual epidemiological situation. In my own 1998 study [5], I estimated that these local surveys were fairly representative, but de Silva and colleagues believe that they are not. They argue that my assumption was undoubtedly too optimistic. Let’s hope that de Silva and colleagues’ study will encourage clinicians and health authorities to report snakebite cases and deaths more accurately.

**Making Antivenom More Accessible**

A better knowledge of morbidity and mortality due to snakebite would lead to improved management, and it may reduce the case fatality rate and mortality (though perhaps not the incidence). Armed with better information on the global burden of snakebite, antivenom manufacturers would be able to better regulate production, and medical authorities could distribute antivenoms to where they are most useful and needed. In order to obtain better knowledge on snakebite morbidity and mortality, we need to standardize methods for collecting data, including well-designed hospital and household surveys. De Silva and colleagues’ study is a preliminary, but essential, step in improving accessibility of antivenoms and the treatment of snakebite.

**References**

1. Stock RP, Massougbodji A, Alagon A, Chippaux JP. (2007) Bringing antivenom to sub-Saharan Africa. Nat Biotechnol 25: 173-177.
2. Chippaux JP (1998) The development and use of immunotherapy in Africa. Toxicon 36: 1501-1506.
3. Chippaux JP (2002) The treatment of snake bites: Analysis of requirements and assessment of therapeutic efficacy in tropical Africa. In: Ménez A, editor. Perspectives in molecular toxicology. Chichester (UK): John Wiley & Sons. pp. 457-472.
4. Swareep S, Grab B (1954) Snake bite mortality in the world. Bull World Health Organ 10: 35-76.
5. Chippaux JP (1998) Snake-bites: Appraisal of the global situation. Bull World Health Organ 76: 515-524.
6. Kasturiratne A, Wickremasinghe AR, de Silva N, Gunawardena NK, Pathmeswaran A, et al. (2008) Estimating the global burden of snake bite: A literature analysis. PLoS Med 5: e218. doi:10.1371/journal.pmed.0050218
7. Coombs MD, Dunachie SJ, Brooker S, Haynes J, Church J, et al. (1997) Snake bites in Kenya: A preliminary survey of four areas. Trans R Soc Trop Med Hyg 91: 319-321.
8. Newman WJ, Moran NF, Theakston RDG, Warrell DA, Wilkinson D (1997) Traditional Treatments for snake bite in a rural African community. Ann Trop Med Parasitol 91: 967-969.
9. Luoaresuwan S, Viravan C, Warrell DA (1988) Factors contributing to fatal snake bite in the rural tropics: Analysis of 46 cases in Thailand. Trans R Soc Trop Med Hyg 82: 930-934.
10. Sharma SK, Chappuis F, Jha N, Bovier PA, Loutan L, et al. (2004) Impact of snake bites and determinants of fatal outcomes in southeastern Nepal. Am J Trop Med Hyg 71: 234-238.
11. Otero R, Gutiérrez J, Beatriz Mesa M, Duque E, Rodríguez O, et al. (2002) Complications of Bothrops, Bothriechis, and Bothriopsis snakebites in Colombia. A clinical and epidemiological study of 39 cases attended in a university hospital. Toxicon 40: 1107-1114.
12. Russell FE, Walter FG, Rey TA, Fernandez MC (1997) Snakes and snakebite in Central America. Toxicon 35: 1469-1522.
13. Guyavarch E, Chippaux JP (2005) Methodology for household surveys: The case of two investigations carried out (example of Bandafassi, Senegal) [Article in French]. Bull Soc Pathol Exot 98: 269-272.